Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Hong, Shaodong ^a   Chen, Nan ^b   Fang, Wenfeng ^a   Zhan, Jianhua ^a   Liu, Qing ^a   Kang, Shiyang ^a   He, Xiaobo ^b   Liu, Lin ^b   Zhou, Ting ^a   Huang, Jiaxing ^b   Chen, Ying ^b   Qin, Tao ^a   Zhang, Yaxiong ^a   Ma, Yuxiang ^a   Yang, Yunpeng ^a   Zhao, Yuanyuan ^a   Huang, Yan ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

EML4 ALK; immunotherapy; NSCLC; PD 1; PD L1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CRIZOTINIB; GAMMA INTERFERON; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; SCH 772984; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NON SMALL CELL LUNG CANCER; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA EXTRACTION;

EID: 84961564399     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1094598     Document Type: Article

References (32)

1. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
2. P.Martinez, A.Martinez-Marti, A.Navarro, S.Cedres, E.Felip. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate. Lung Cancer 2014; 84:97-100; PMID:24582269; http://dx.doi.org/10.1016/j.lungcan.2014.01.018
3. S.Dearden, J.Stevens, Y.L.Wu, D.Blowers. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24:2371-6; PMID:23723294; http://dx.doi.org/10.1093/annonc/mdt205
4. S.Hong, W.Fang, Z.Hu, T.Zhou, Y.Yan, T.Qin, Y.Tang, Y.Ma, Y.Zhao, C.Xue et al. A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. Sci Rep 2014; 4:7268; PMID:25434695; http://dx.doi.org/10.1038/srep07268
5. Y.Pan, Y.Zhang, Y.Li, H.Hu, L.Wang, H.Li, R.Wang, T.Ye, X.Luo, Y.Zhang et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 2014; 84:121-6; PMID:24629636; http://dx.doi.org/10.1016/j.lungcan.2014.02.007
6. T.Mitsudomi, S.Morita, Y.Yatabe, S.Negoro, I.Okamoto, J.Tsurutani, T.Seto, M.Satouchi, H.Tada, T.Hirashima et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-8; PMID:20022809; http://dx.doi.org/10.1016/S1470-2045(09)70364-X
7. L.V.Sequist, B.A.Waltman, D.Dias-Santagata, S.Digumarthy, A.B.Turke, P.Fidias, K.Bergethon, A.T.Shaw, S.Gettinger, A.K.Cosper et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26; PMID:21430269; http://dx.doi.org/10.1126/scitranslmed.3002003
8. Y.Lin, X.Wang, H.Jin. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 2014; 4:411-35; PMID:25232485
9. R.Katayama, A.T.Shaw, T.M.Khan, M.Mino-Kenudson, B.J.Solomon, B.Halmos, N.A.Jessop, J.C.Wain, A.T.Yeo, C.Benes et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4:120ra17; PMID:22277784; http://dx.doi.org/10.1126/scitranslmed.3003316
10. H.Isozaki, N.Takigawa, K.Kiura. Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers (Basel) 2015; 7:763-83; PMID:25941796; http://dx.doi.org/10.3390/cancers7020763
11. I.Mellman, G.Coukos, G.Dranoff. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
12. S.L.Topalian, G.J.Weiner, D.M.Pardoll. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi.org/10.1200/JCO.2011.38.0899
13. J.Brahmer, K.L.Reckamp, P.Baas, L.Crino, W.E.Eberhardt, E.Poddubskaya, S.Antonia, A.Pluzanski, E.E.Vokes, E.Holgado et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373(2):123-35
14. R.Ibrahim, R.Stewart, A.Shalabi. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol 2015; 42:474-83; PMID:25965366; http://dx.doi.org/10.1053/j.seminoncol.2015.02.007
15. K.Ota, K.Azuma, A.Kawahara, S.Hattori, E.Iwama, J.Tanizaki, T.Harada, K.Matsumoto, K.Takayama, S.Takamori et al. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Clin Cancer Res 2015; 21(17):4014-21; PMID:26019170; http://dx.doi.org/10.1158/1078-0432.CCR-15-0016
16. K.Azuma, K.Ota, A.Kawahara, S.Hattori, E.Iwama, T.Harada, K.Matsumoto, K.Takayama, S.Takamori, M.Kage et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014; 25:1935-40; PMID:25009014; http://dx.doi.org/10.1093/annonc/mdu242
17. Y.Tang, W.Fang, Y.Zhang, S.Hong, S.Kang, Y.Yan, N.Chen, J.Zhan, X.He, T.Qin et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015; 6(16):14209-19; PMID:25895031; http://dx.doi.org/10.18632/oncotarget.3694
18. N.Chen, W.Fang, J.Zhan, S.Hong, Y.Tang, S.Kang, Y.Zhang, X.He, T.Zhou, T.Qin et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol 2015; 10:910-23; PMID:25658629; http://dx.doi.org/10.1097/JTO.0000000000000500
19. E.A.Akbay, S.Koyama, J.Carretero, A.Altabef, J.H.Tchaicha, C.L.Christensen, O.R.Mikse, A.D.Cherniack, E.M.Beauchamp, T.J.Pugh et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3(12):1355-63; PMID:24078774; http://dx.doi.org/10.1158/2159-8290.CD-13-0310
20. W.Fang, J.Zhang, S.Hong, J.Zhan, N.Chen, T.Qin, Y.Tang, Y.Zhang, S.Kang, T.Zhou et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014; 5:12189-202; PMID:25361008; http://dx.doi.org/10.18632/oncotarget.2608
21. Y.Li, K.Pan, L.Z.Liu, Y.Q.Li, M.F.Gu, H.Zhang, W.X.Shen, J.C.Xia, J.J.Li. Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma. PLoS One 2015; 10:e0130620; PMID:26098948; http://dx.doi.org/10.1371/journal.pone.0130620
22. J.Zhou, D.Weng, F.Zhou, K.Pan, H.Song, Q.Wang, H.Wang, H.Wang, Y.Li, L.Huang et al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol Immunother 2009; 58:1587-97; PMID:19221746; http://dx.doi.org/10.1007/s00262-009-0668-9
23. C.M.Dowling, O.C.Herranz, P.A.Kiely. Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells. Biosci Rep 2014; 34:e00126; PMID:24935351; http://dx.doi.org/10.1042/BSR20140031
24. Z.Teng, X.Kuang, J.Wang, X.Zhang. Real-time cell analysis–a new method for dynamic, quantitative measurement of infectious viruses and antiserum neutralizing activity. J Virol Methods 2013; 193:364-70; PMID:23835032; http://dx.doi.org/10.1016/j.jviromet.2013.06.034
25. J.M.Boland, E.D.Kwon, S.M.Harrington, J.A.Wampfler, H.Tang, P.Yang, M.C.Aubry. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013; 14:157-63; PMID:22868219; http://dx.doi.org/10.1016/j.cllc.2012.05.006
26. Y.Y.Chen, L.B.Wang, H.L.Zhu, X.Y.Li, Y.P.Zhu, Y.L.Yin, F.LüFZ, Z.L.Wang, J.M.Qu. Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J 2013; 28:147-51; PMID:24074616; http://dx.doi.org/10.1016/S1001-9294(13)60040-1
27. V.Velcheti, K.A.Schalper, D.E.Carvajal, V.K.Anagnostou, K.N.Syrigos, M.Sznol, R.S.Herbst, S.N.Gettinger, L.Chen, D.L.Rimm. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94:107-16; PMID: 24217091 http://dx.doi.org/10.1038/labinvest.2013.130
28. E.A.Akbay, S.Koyama, J.Carretero, A.Altabef, J.H.Tchaicha, C.L.Christensen, O.R.Mikse, A.D.Cherniack, E.M.Beauchamp, T.J.Pugh et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3:1355-63; PMID:24078774; http://dx.doi.org/10.1158/2159-8290.CD-13-0310
29. M.Marzec, Q.Zhang, A.Goradia, P.N.Raghunath, X.Liu, M.Paessler, H.Y.Wang, M.Wysocka, M.Cheng, B.A.Ruggeri et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008; 105:20852-7; PMID:19088198; http://dx.doi.org/10.1073/pnas.0810958105
30. A.T.Parsa, J.S.Waldron, A.Panner, C.A.Crane, I.F.Parney, J.J.Barry, K.E.Cachola, J.C.Murray, T.Tihan, M.C.Jensen et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84-8; PMID:17159987; http://dx.doi.org/10.1038/nm1517
31. J.J.Luke, P.A.Ott. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic. Expert Opin Pharmacother 2013; 14:2457-62; PMID:24138302; http://dx.doi.org/10.1517/14656566.2013.849244
32. N.Srivastava, D.McDermott. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 2014; 6:279-89; PMID:25018651; http://dx.doi.org/10.2147/CMAR.S64979